Myostellar is a discovery-stage Australian biotechnology spin-out from Monash University focusing on developing novel therapeutics for skeletal muscle regeneration. Our core technology is founded upon the key science from the laboratories of co-founders Prof. Peter Currie and A/Prof Mikael Martino at the Australian Regenerative Medicine Institute, where the team discovered a novel mechanism of action for muscle regeneration. Myostellar seeks to translate these scientific findings to develop highly differentiated, first-in-class fusion protein therapeutics for the regeneration of skeletal muscle with minimal fibrosis, with the lead program in Duchenne muscular dystrophy. At present, there are no approved therapeutics dedicated to promoting the regeneration and repair of skeletal muscle in clinical settings – a significant unmet need which forms a considerable burden on both the global and Australian health and medical systems. Our long-term vision is to become a leader in this space with a robust pipeline of therapeutic products that will set the gold standard in clinical treatment for conditions/diseases of muscle loss.